key: cord-0727904-s0kvs39x authors: Conti, Maria Giulia; Terreri, Sara; Terrin, Gianluca; Natale, Fabio; Pietrasanta, Carlo; Salvatori, Guglielmo; Brunelli, Roberto; Midulla, Fabio; Papaevangelou, Vassiliki; Carsetti, Rita; Angelidou, Asimenia title: SARS-CoV-2 infection versus vaccination in pregnancy: Implications for maternal and infant immunity date: 2022-05-10 journal: Clin Infect Dis DOI: 10.1093/cid/ciac359 sha: 2c21e6cb1934b5251a511164e5f682e2cfdcabb1 doc_id: 727904 cord_uid: s0kvs39x BACKGROUND: SARS-CoV-2 infection has been associated with adverse maternal and neonatal outcomes, yet uptake of SARS-CoV-2 vaccines during pregnancy and lactation has been slow. As a result, millions of pregnant and lactating women and their infants remain susceptible to the virus. METHODS: We measured Spike-specific immunoglobulin G (anti-S IgG) and A (anti-S IgA) in serum and breastmilk (BM) samples from 3 prospective mother-infant cohorts recruited in two academic medical centers. The primary aim was to determine the impact of maternal SARS-CoV-2 immunization vs infection and their timing on systemic and mucosal immunity. RESULTS: The study included 28 mothers infected with SARS-CoV-2 in late pregnancy (INF), 11 uninfected mothers who received 2 doses of the BNT162b2 vaccine in the latter half of pregnancy (VAX-P) and 12 uninfected mothers who received 2 doses of BNT162b2 during lactation (VAX-L). VAX dyads had significantly higher serum anti-S IgG compared to INF dyads (p < .0001), while INF mothers had higher BM: serum anti-S IgA ratios compared to VAX mothers (p = .0001). Median IgG placental transfer ratios were significantly higher in VAX-P compared to INF mothers (p < 0.0001). There was a significant positive correlation between maternal and neonatal serum anti-S IgG after vaccination (r = 0.68, p = 0.013), but not infection. CONCLUSIONS: BNT161b2 vaccination in late pregnancy or lactation enhances systemic immunity through serum anti-S Ig, while SARS-CoV-2 infection induces mucosal over systemic immunity more efficiently through BM Ig production. Next generation vaccines boosting mucosal immunity could provide additional protection to the mother-infant dyad. Future studies should focus on identifying the optimal timing of primary and/or booster maternal vaccination for maximal benefit. and Prevention (CDC) suggests that pregnant women with severe acute respiratory syndrome 6 coronavirus 2 (SARS-CoV-2) infection are more likely to require intensive care or mechanical 7 ventilation than nonpregnant women of reproductive age [3], while two large retrospective 8 multicenter studies in the US found that women with COVID-19 giving birth had higher rates of 9 mortality, sepsis, mechanical ventilation, ICU admission, and preterm birth than women without 10 COVID-19 [4] [5] [6] . COVID-19 diagnosis in the 2 nd vs 3 rd trimester of pregnancy differentially 11 affected the immune response at delivery, suggesting that the timing of immune stimulation is an 12 important parameter [7] . More specifically, women infected during the 3 rd trimester exhibited 13 cytokine signatures that clinically correlated with a high incidence of late pregnancy-and 14 postpartum-related complications, particularly, preeclampsia and fetal growth restriction [8] . 15 Despite poor maternal perinatal outcomes, vertical SARS-CoV-2 infection is rare [9] and the 16 prevalence of neonatal SARS-CoV-2 infection is low compared to other age groups, likely due to 17 placental protective mechanisms limiting viral entry [10] . However, neonates remain susceptible 18 to horizontally transmitted infection owing to their distinct immune system [11] . Transplacental 19 antibody (Ab) transfer, starting around 28 weeks of gestation, is the main form of passive 20 immunization for young infants, with protection persisting for the first 3-5 months of life. Immunological outcomes after maternal SARS-CoV-2 vaccination during pregnancy and 8 lactation are sparse but urgently needed to inform maternal immunization practices. We present 9 data on vaccine-vs natural infection-induced anti-S Ab titers in the serum and BM of pregnant 10 and lactating mothers and their newborns. Our primary goal was to determine relative Ab 11 presence in maternal serum and BM after maternal perinatal SARS-CoV-2 infection or 12 vaccination, and how their timing may affect systemic and mucosal Ab transfer from the mother 13 to the newborn. Study Design 16 We designed a prospective study including 3 convenience cohorts of mothers and their infants: Maternal peripheral blood as well as neonatal (cord and peripheral) blood samples were collected 6 as shown in Figure 1 . Each newborn born to an INF mother routinely had peripheral blood 7 drawn at 48 hours of life (2d) as part of the hospital protocol, while healthy non-exposed 8 newborns born to VAX-P mothers were not routinely phlebotomized after birth, so cord blood 9 was collected instead. Serum specimens were collected from INF mothers at 2 days after 10 delivery (median of 5 days after infection) and 60 days after infection, from VAX-P mothers 60 11 days post-second vaccine dose and from VAX-L mothers 10 days post-second vaccine dose. Cord blood was collected from the umbilical vein after delivery and peripheral blood was 13 collected by venipuncture into serum separator tubes. Blood was centrifuged at 1400 rpm for 5 14 minutes at room temperature. In clinically stable mothers who were willing to pump milk, BM 15 was collected after nipple disinfection using a manual sterile pump. Serum and BM samples 16 were aliquoted into cryogenic vials and stored at −80°C until further analysis. We analyzed serum and BM specimens from mothers infected with SARS-CoV-2 during Table 1 . Among pregnant participants, the 16 mean gestational age at the first vaccine dose was 26 weeks, with 5 women (45%) receiving their 17 first vaccine dose in the second trimester and 6 (55%) in the third trimester. The exact timing of 18 serum and BM sampling in relation to infection or vaccination (2 nd dose) is summarized in Table 19 1. 20 Anti-S IgG in maternal serum was significantly higher in vaccinated vs infected mothers ( Figure 21 2, Table 2 ). Inter-individual variability in IgG concentrations was greater in infected, compared 22 to vaccinated women (Figure 2A) . In INF mothers, positivity for SARS-CoV-2 was detected at 14 Until such data becomes available, population-derived statistics can be utilized to infer benefit-15 risk ratios for pregnant women. 16 Our study which included cohorts of women during pregnancy and postpartum provides 17 immunological data supporting vaccination of mothers during pregnancy or after delivery. Our results support the notion that vaccination is of substantial 1 benefit during pregnancy, given the risk SARS-CoV-2 infection poses to both mother and infant. A combination of vaccination before and after delivery may comprise an optimal strategy to 3 maximize maternal immunization benefit to the offspring. Future efforts should focus on 4 development of vaccine technologies that also robustly activate mucosal immunity. Alternative theories: Pregnancy and immune tolerance Pregnancy, Viral 4 Infection, and COVID-19 Characteristics of Women of Reproductive Age with SARS-CoV-2 Infection by Pregnancy Status -United Characteristics and Outcomes of Women With COVID-19 Giving Birth at US Academic Centers During the COVID-19 Pandemic Severe Illness Among US Delivery Hospitalizations With and 13 SARS-CoV-2 Infection During Pregnancy 16 and Associated Perinatal Health Outcomes: A National US Cohort Study. The Journal of 17 infectious diseases 2022 Maternal-Fetal Immunologic Response to SARS-19 Infection in a Symptomatic Vulnerable Population: A Prospective Cohort. The 20 Journal of infectious diseases 2022